The INTERPAT Winter General Assembly, will be taking place virtually on the 9th & 10th November from 13.00 CET until 16.00 CET on both days. This event is for the INTERPAT Membership and invitations have also been extended to the Trade Associations, along with guest speakers.
Launching the IP PACT: Our approach to Intellectual Property with patient and societal benefit at its core.
Medical innovations driven by the biopharmaceutical industry have played a fundamental role in helping people live longer, healthier lives. As the global population's health needs become increasingly complex, it is ever more essential that we research and develop life-saving medicines and vaccines to meet these challenges. Intellectual Property (IP) has been central to great scientific advances and for ensuring that patients have access to this innovation. IP helps foster long term investment to benefit patients – today and tomorrow.
The economic impact of changing the environment for innovation in Argentina-Applying the lessons of Asia to Latin America (JWIP)
An article entitled " The Economic impact of changing the environment for innovation in Argentina-Applying the lessons of Asia to Latin America. " has been published in the Journal of World Intellectual Property. Full article available here. The authors were commissioned to conduct this research by Interpat.
On 19 March 2020, the global biopharmaceutical industry, represented by high-level executives/ CEO’s, took part in a virtual media briefing highlighting industry’s efforts and future commitments to address the current global coronavirus (COVID-19) crisis. The strong line-up of company representatives marks an important milestone in showcasing the industry’s commitments to accelerate efforts to develop skills, technology and resources to bring safe, effective diagnostics, treatments and vaccines to patients around the world. The severity of the COVID-19 pandemic ...
INTERPAT's General Assembly which was due to take place in June 2020 in Boston,USA has been postponed due to the current worldwide COVID-19 pandemic situation.
As a science-driven industry that aims to address some of the world’s biggest health care challenges, the research-based biopharmaceutical industry is uniquely positioned to respond rapidly to COVID-19. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), representing the world’s leading biopharmaceutical companies, today confirmed that having already mobilized on an unprecedented scale to respond to the COVID-19 pandemic, they commit to do more. The biopharmaceutical industry commits to accelerate its effort to use its skills, ...
Intellectual Property Rights are at the heart of our biopharma industry innovation. They provide key incentives for research and development of new medicines and the improvement of existing ones. Further resources can be found on the IFPMA website and in the links below: Why Intellectual Property matters? Value of Innovation Sustainable Innovation
INTERPAT asked Charles River Associates (CRA) to identify and quantify the economic benefits from strengthening the environment for innovation in Brazil. The study was launched in Brasilia on 12th March 2020. The executive summary is available in English and Portuguese. The full report will be published shortly. Executive Summary in English Executive Summary in Portuguese
INPI will be celebrating its 50 year anniversary in December 2020 and this important milestone will be addressed in a joint event with the Parliamentary Front in Defense of Intellectual Property and Combating Piracy, on March 12,08h00, in Brasília. (Câmara dos Deputados – Anexo IV 10o Andar – Restaurante Senac) The Front will hold a breakfast sponsored by INTERPAT, Interfarma and INPI for the launch of its activities this year, when the international CRA study “Value of intellectual property for health and growth – The economic benefits of strengthening the ...